{
    "clinical_study": {
        "@rank": "95907", 
        "arm_group": [
            {
                "arm_group_label": "Everolimus", 
                "arm_group_type": "Experimental", 
                "description": "Everolimus/Tacrolimus/Methylprednisolone & Prednisolone"
            }, 
            {
                "arm_group_label": "Mycophenolate mofetil", 
                "arm_group_type": "Active Comparator", 
                "description": "Mycophenolate mofetil/Tacrolimus/ Methylprednisolone & Prednisolone"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to understand the effects of everolimus on tacrolimus\n      pharmacokinetics (pk) in patients receiving de novo kidney transplants."
        }, 
        "brief_title": "Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Kidney Transplantation", 
        "detailed_description": {
            "textblock": "Multidrug immunosuppression regimens have synergistic effects which allow the use of lower\n      doses of individual agents. These regimens generally include calcineurin inhibitors (CNIs:\n      cyclosporine or tacrolimus), mammalian target of rapamycin (mTOR) inhibitors (everolimus or\n      sirolimus), and corticosteroids. CNIs and mTOR inhibitors are substrates for cytochrome P450\n      3A4 (CYP3A4) and P-glycoprotein (P-gp); in addition, cyclosporine is a inhibitor of CYP3A4\n      and P-gp. Therefore, concomitant administration of those drugs may alter their serum levels.\n\n      It is remained to be further evaluated whether the pharmacokinetics or clinical efficacy of\n      concomitant medications will be affected when the regimens contain everolimus in clinical\n      practice. Mycophenolate mofetil (MMF) has no effect on pharmacokinetics of tacrolimus;\n      therefore, MMF is used as a control to understand the effects of everolimus on\n      pharmacokinetics of tacrolimus in patients receiving de novo kidney transplants."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  De novo kidney transplants\n\n          -  20 - 65 years old\n\n          -  aspartate aminotransferase/alanine aminotransferase within 2 times the upper limit of\n             normal range\n\n        Exclusion criteria:\n\n          -  Pregnancy\n\n          -  Tuberculosis\n\n          -  Hepatitis B or C carrier status\n\n          -  Human immunodeficiency virus-positive status\n\n          -  Retransplantation or multiorgan transplantation\n\n          -  History of rheumatoid arthritis\n\n          -  Use of drugs that might have enhanced or inhibited CYP3A4 or P-gp activity"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02077556", 
            "org_study_id": "201312011MINA"
        }, 
        "intervention": [
            {
                "arm_group_label": "Everolimus", 
                "description": "Everolimus: 1 mg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 3-8 ng/mL", 
                "intervention_name": "Everolimus", 
                "intervention_type": "Drug", 
                "other_name": "Certican"
            }, 
            {
                "arm_group_label": "Mycophenolate mofetil", 
                "description": "Mycophenolate mofetil: 10-15 mg/kg orally every 12 hours from post-operation day 1 (decrease 50% dose if white blood cell < 4000/mcL)", 
                "intervention_name": "Mycophenolate mofetil", 
                "intervention_type": "Drug", 
                "other_name": "CellCept"
            }, 
            {
                "arm_group_label": [
                    "Everolimus", 
                    "Mycophenolate mofetil"
                ], 
                "description": "Tacrolimus: 0.05-0.075 mg/kg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 8-12 ng/mL", 
                "intervention_name": "Tacrolimus", 
                "intervention_type": "Drug", 
                "other_name": "Prograf"
            }, 
            {
                "arm_group_label": [
                    "Everolimus", 
                    "Mycophenolate mofetil"
                ], 
                "description": "Methylprednisolone: 50 mg iv every 6 hours on post-operation day 1, 40 mg iv every 6 hours on post-operation day 2, 30 mg iv every 6 hours on post-operation day 3, 20 mg iv every 6 hours on post-operation day 4, 20 mg iv every 8 hours on post-operation day 5, 20 mg iv every 12 hours on post-operation day 6, 20 mg iv on post-operation day 7", 
                "intervention_name": "Methylprednisolone", 
                "intervention_type": "Drug", 
                "other_name": "Solu-Medrol"
            }, 
            {
                "arm_group_label": [
                    "Everolimus", 
                    "Mycophenolate mofetil"
                ], 
                "description": "Prednisolone: 20 mg orally once a day from post-operation day 8 to post-operation week 4, then titrated gradually", 
                "intervention_name": "Prednisolone", 
                "intervention_type": "Drug", 
                "other_name": "Predonine"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Methylprednisolone acetate", 
                "Prednisolone acetate", 
                "Methylprednisolone", 
                "Methylprednisolone Hemisuccinate", 
                "Prednisolone", 
                "Prednisolone hemisuccinate", 
                "Prednisolone phosphate", 
                "Mycophenolic Acid", 
                "Sirolimus", 
                "Mycophenolate mofetil", 
                "Everolimus", 
                "Tacrolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "tacrolimus, everolimus, pharmacokinetics, drug interaction", 
        "lastchanged_date": "April 24, 2014", 
        "location": {
            "contact": {
                "email": "mengkuntsai@ntu.edu.tw", 
                "last_name": "Meng-Kun Tsai", 
                "phone": "+886-972651461"
            }, 
            "facility": {
                "address": {
                    "city": "Taipei", 
                    "country": "Taiwan"
                }, 
                "name": "National Taiwan University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients: Using Mycophenolate Mofetil as a Control", 
        "overall_contact": {
            "email": "flwu@ntu.edu.tw", 
            "last_name": "Fe-Lin Lin Wu", 
            "phone": "+886-2-3366 8784"
        }, 
        "overall_official": {
            "affiliation": "National Taiwan University Hospital", 
            "last_name": "Meng-Kun Tsai", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan: Department of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Pharmacokinetic parameters include the maximum concentration, trough concentration, area under the whole-blood concentration-time curve between 0 and 12 hours, time to maximum concentration, volume of distribution at steady state, and clearance at steady state.", 
            "measure": "Pharmacokinetic profiles", 
            "safety_issue": "No", 
            "time_frame": "Post-operation day 8-10"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02077556"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Acute rejection", 
            "safety_issue": "No", 
            "time_frame": "Within the first 2 weeks post-transplantation"
        }, 
        "source": "National Taiwan University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Taiwan University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}